Anzeige
Mehr »
Login
Donnerstag, 24.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
KI-Energiekrise: Wie dieser Small Cap die nukleare Zukunft des Silicon Valley befeuern könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14M2J | ISIN: IE00BTN1Y115 | Ticker-Symbol: 2M6
Tradegate
24.10.24
17:13 Uhr
85,15 Euro
-0,40
-0,47 %
1-Jahres-Chart
MEDTRONIC PLC Chart 1 Jahr
5-Tage-Chart
MEDTRONIC PLC 5-Tage-Chart
RealtimeGeldBriefZeit
85,1185,2317:15
85,1285,2017:15
GlobeNewswire (Europe)
155 Leser
Artikel bewerten:
(0)

Royal Philips: Philips and Medtronic advocacy partnership aims to help accelerate access to life-saving treatments

October 24, 2024

Both companies also join the newly established World Stroke Organization Advocacy Coalition

Amsterdam, the Netherlands - Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke care is crucial to saving lives and reducing long-term disability. As leaders in stroke diagnosis and treatment, the two organizations are advocating on raising awareness around the potential health and economic benefits for patients, their families and societies of improving access to timely stroke diagnosis and treatment.

Philips and Medtronic Neurovascular also further expanded and strengthened their partnerships with the World Stroke Organization. This WSO-led coalition brings together diverse stakeholders, including healthcare professionals, patient groups, and policymakers, to develop coordinated strategies that address the global burden of stroke. The two companies are already working together with the World Stroke Organization to share the latest research, exchange best practices, drive improvements and advance the stroke policy agenda.

A stroke is typically an acute event, mostly caused by a blockage in a blood vessel in the brain that prevents adequate blood supply to brain tissue and leads to permanent loss of brain cells. It is a leading cause of disability and death worldwide, affecting an estimated 12 million peopleglobally every year, including an increasing number of young people. The direct and indirect costs are conservatively estimated to be around USD 900 billionannually and are expected to almost double over the next 25 years.

Philips and Medtronic Neurovascular are advocating for a global network of stroke care centers that can deliver comprehensive care, from early diagnosis to rehabilitation. Their joint efforts focus on three key areas:

  • Raising awareness: Promoting public understanding of stroke symptoms and the importance of seeking immediate care.
  • Improving access to treatment: Expanding the number of stroke-ready hospitals and providing training to healthcare professionals on the latest interventional techniques.
  • Leveraging technology and innovation: Utilizing advanced imaging and digital health tools to create integrated stroke care systems that support early diagnosis, effective treatment, and post-procedure monitoring.

The collaboration will be highlighted at the upcoming World Stroke Congressand the World Health Assembly, where they emphasized the need for increased investments in stroke care infrastructure and supportive policy changes.

"Our new partnership with Medtronic Neurovascular and the ongoing collaboration with the World Stroke Organization highlights our shared commitment to transforming stroke care. With advanced technologies and a focus on collaboration, the time to act is now to ensure that stroke patients have timely stroke care - no matter where they live," said Carla Goulart Peron, Chief Medical Officer, Philips.

"Stroke care is a race against time, and by joining forces with Philips, we can help accelerate access to life-saving treatments like mechanical thrombectomy. Together, we are advocating for necessary investments in stroke care infrastructure to reduce the burden on patients and healthcare systems globally," said Signe Haughton, Chief of Staff, Senior Director of Medical & Government Affairs, Medtronic Neurovascular.

WSO Advocacy Coalition
Philips' partnershipwith the World Stroke Organization, established in 2023, has now been further expanded and strengthened by Philips' involvement in the WSO Advocacy Coalition. While the initial partnership focused on improving access to high-quality stroke care globally, this new collaboration deepens Philips' role in global stroke advocacy. By joining the WSO Advocacy Coalition, Philips is now part of a global network that actively works on healthcare policy, raise public awareness, and advocate for increased investment in stroke care infrastructure.

[1] World Stroke Organization - Time for a Revolution in Stroke Care
[2] The Lancet Neurology - Pragmatic solutions to reduce the global burden of stroke

For further information, please contact:

Joost Maltha
Philips External Relations
Tel. : +31 6 10558116
E-mail : joost.maltha@philips.com

Kelli Lynch
Medtronic Public Relations
Tel.: + 1 203-500-3328
E-mail: Kelli.b.lynch@medtronic.com

About Royal Philips
Royal Philips.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.comand follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Attachments

  • Stroke patient (https://ml-eu.globenewswire.com/Resource/Download/ac1c7213-2642-49d0-8342-9bee4c669f6f)
  • Stroke patient recovering (https://ml-eu.globenewswire.com/Resource/Download/eeb7b37b-99b0-4d93-8643-67bf264f5dec)
  • Philips stroke Azurion interventional suite (https://ml-eu.globenewswire.com/Resource/Download/af1c939c-6875-487b-8f01-d68ee21eb266)

© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.